老年男性停止有组织筛查后的前列腺癌死亡率:欧洲前列腺癌筛查随机研究鹿特丹部分的长期结果
本研究纳入7052名参与欧洲前列腺癌筛查随机研究鹿特丹筛查臂、末次筛查时年龄70-74岁且最多三轮筛查未诊断前列腺癌的男性,评估至85岁的前列腺癌特异性死亡率(PCSM)。中位随访16年,全部男性至85岁累积PCSM为0.54%(95%CI 0.40-0.70);PSA<2 ng/ml者为0.11%(95%CI 0.05-0.27),PSA 2-3 ng/ml者为0.85%(95%CI 0.47-1.5),PSA≥6.5 ng/ml且无既往良性活检者为6.8%(95%CI 3.1-15)。
要点
- 70-74岁既往接受PSA筛查未诊断前列腺癌者至85岁PCSM仅0.54%。
- PSA<2 ng/ml者至85岁累积PCSM为0.11%。
- PSA 2-3 ng/ml者至85岁累积PCSM为0.85%。
核心结论
- 70-74岁既往接受PSA筛查未诊断前列腺癌的男性至85岁死于前列腺癌的风险很低。
- 作者认为,PSA<3.0 ng/ml或有既往良性前列腺活检的男性可停止筛查。
- 作者认为,PSA水平较高且无既往活检者若预期寿命超过10年可考虑继续筛查。
研究设计与样本
- 欧洲前列腺癌筛查随机研究鹿特丹部分筛查臂的长期随访分析。
- 纳入7052名男性,末次筛查时年龄70-74岁,最多接受三轮筛查且未诊断前列腺癌。
- 中位随访16年,评估至85岁的前列腺癌特异性死亡率累积发生率。
- 采用竞争风险回归评估PCSM的潜在预测因素。
主要发现
- 全部男性至85岁累积PCSM为0.54%(95%CI 0.40-0.70)。
- PSA<2 ng/ml者至85岁累积PCSM为0.11%(95%CI 0.05-0.27)。
- PSA 2-3 ng/ml者至85岁累积PCSM为0.85%(95%CI 0.47-1.5)。
- PSA≥6.5 ng/ml且无既往良性活检者至85岁累积PCSM为6.8%(95%CI 3.1-15)。
- PSA(sHR 2.0;95%CI 1.7-2.3)、既往良性前列腺活检(sHR 0.41;95%CI 0.23-0.72)和高血压(sHR 0.48;95%CI 0.25-0.91)与PCSM显著相关。
关键数值与推荐
- 全部男性至85岁累积PCSM为0.54%(95%CI 0.40-0.70)。
- PSA<2 ng/ml者至85岁累积PCSM为0.11%(95%CI 0.05-0.27)。
- PSA 2-3 ng/ml者至85岁累积PCSM为0.85%(95%CI 0.47-1.5)。
- PSA≥6.5 ng/ml且无既往良性活检者至85岁累积PCSM为6.8%(95%CI 3.1-15)。
- PSA的sHR为2.0(95%CI 1.7-2.3),既往良性前列腺活检的sHR为0.41(95%CI 0.23-0.72),高血压的sHR为0.48(95%CI 0.25-0.91)。
临床怎么用
- 作者认为,PSA<3.0 ng/ml或有既往良性前列腺活检的男性可停止筛查。
- 作者认为,PSA水平较高且无既往活检者若预期寿命超过10年可考虑继续筛查。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal timing for discontinuing screening of prostate cancer (PCa) in elderly men is currently not known and remains debated. OBJECTIVE: To assess prostate cancer-specific mortality (PCSM) in elderly men who previously underwent prostate-specific antigen (PSA)-based screening and to identify those who may benefit from continued screening. DESIGN, SETTING, AND PARTICIPANTS: A total of 7052 men, who participated in the screening arm of the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer and were aged 70-74 yr at their last screening visit after undergoing a maximum of three screening rounds without being diagnosed with PCa, were included. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The cumulative incidence of PCSM by the age of 85 yr was assessed. Additionally, a competing risk regression was performed to assess the potential predictors of PCSM. RESULTS AND LIMITATIONS: The median follow-up was 16 yr. The cumulative incidence of PCSM by the age of 85 yr was 0.54% (95% confidence interval [CI]: 0.40-0.70) in all men, 0.11% (95% CI: 0.05-0.27) in men with PSA <2 ng/ml, 0.85% (95% CI: 0.47-1.5) in men with PSA 2-3 ng/ml, and 6.8% (95% CI: 3.1-15) in men with PSA ≥6.5 ng/ml and no previous benign biopsy. PSA (subdistribution hazard ratio [sHR]: 2.0; 95% CI: 1.7-2.3), previous benign prostate biopsy (sHR: 0.41; 95% CI: 0.23-0.72), and hypertension (sHR: 0.48; 95% CI: 0.25-0.91) were significantly associated with PCSM. CONCLUSIONS: Men aged 70-74 yr who have previously undergone PSA-based screening without receiving a PCa diagnosis have a very low risk of dying from PCa by the age of 85 yr. These data suggest that screening may be discontinued in men with PSA <3.0 ng/ml or previous benign prostate biopsies. Those with higher PSA levels and no prior biopsies may consider continued screening if life expectancy exceeds 10 yr. PATIENT SUMMARY: This study shows that men who participated in a prostate cancer screening trial have a very low risk of dying from prostate cancer if they have not been diagnosed with prostate cancer by the age of 74 yr.
引用
- de Vos II, Remmers S, Hogenhout R, et al. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam. Eur Urol. 2023. PMID: 37919190. doi:10.1016/j.eururo.2023.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。